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Viral infection is a serious complication that can greatly affect patient mortality 3 
and morbidity after allogenic hematopoietic stem cell transplantation (allo-HSCT). 4 
For the early identification of patients who are at high risk for viral infection, we 5 
evaluated the impact of lymphocyte-Area Under the Curve (AUC) as a new 6 
predictive factor for early immune reconstitution after allo-HSCT against viral 7 
infection.  8 
Method 9 
This study included 286 patients who underwent their first allo-HSCT at Kyoto 10 
University Hospital between 2005 and 2017. Lymphocyte-AUC from day 0 to day 11 
15 was calculated in the analysis of HHV-6, and that from day 0 to day 30 was 12 
calculated in the analysis of other viruses (cytomegalovirus (CMV), adenovirus, 13 
BK virus, JC virus, and varicella zoster virus). The risk factors for each viral 14 
reactivation/infection were assessed using multivariate analysis. 15 
Results 16 
The median age at transplantation was 51 (range, 17–68) years. The median 17 
lymphocyte-AUC was 63 (range, 0–5620)/μL at day 15 and 3880 (range, 0–18 
118260)/μL at day 30. An increase in lymphocyte-AUC was significantly 19 
associated with a high frequency of HHV6 reactivation (P=0.033) and a low 20 
frequency of CMV antigenemia (P=0.014). No apparent association was found 21 
between lymphocyte-AUC and reactivation/infection of other viruses. Aplastic 22 
anemia as a primary disease (HR, 5.34; P<0.001) and cord blood as a donor 23 
source (HR, 3.05; P=0.006) were other risk factors for HHV-6 reactivation. The 24 
occurrence of acute graft-versus-host disease (HR 2.21, P<0.001) and recipient 25 
age (HR 1.55, P=0.017) were also risk factors for CMV antigenemia. Higher 26 




lymphocyte-AUC at day 30 was significantly associated with low treatment-1 
related mortality (HR 0.47, P=0.045). 2 
Conclusion 3 
Lymphocyte-AUC may be a good predictive factor for immune reconstitution 4 
against CMV reactivation. It also provides valuable information for predicting 5 
HHV-6 reactivation and treatment-related mortality. 6 
Key words 7 
lymphocyte-AUC, HHV-6, CMV antigenemia, viral reactivation, immune 8 
reconstitution 9 
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 High lymphocyte-AUC was associated with a lower frequency of CMV 3 
antigenemia. 4 
 High lymphocyte-AUC was associated with a lower risk of treatment-related 5 
mortality. 6 
 Lymphocyte-AUC could be a prognostic factor of immune-reconstitution after 7 
HSCT. 8 
 High lymphocyte-AUC was associated with a high frequency of HHV-6 9 
reactivation 10 
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Viral infections continue to be serious complications that negatively impact patient 2 
survival after allogenic hematopoietic stem cell transplantation (allo-HSCT). After 3 
allo-HSCT, patients often develop reactivation of and infection by various latent 4 
viruses, including cytomegalovirus (CMV), varicella zoster virus (VZV), human 5 
herpes virus-6 (HHV-6), adenovirus (ADV), BK virus (BKV), and JC virus (JCV), 6 
due to their prolonged and strongly immunosuppressed background1.  7 
 8 
Since both the number of transplantations from various stem cell sources such 9 
as cord blood unit and the number of transplantations performed for high-risk 10 
patients are increasing, the management of viral infection is becoming even more 11 
important to improve clinical outcomes of HSCT. However, preventive measures 12 
and effective treatments against these viruses are still limited and remain largely 13 
dependent on immune reconstitution in the recipients themselves. However, as 14 
seen in the prophylactic administration of acyclovir/valacyclovir against VZV1,2 15 
and pre-emptive therapies against CMV infections diagnosed via serum antigen 16 
or real-time polymerase chain reaction (PCR)3,4, early intervention leads to 17 
favorable outcomes. It is important to identify high-risk patients for viral infection 18 
in the early stage after HSCT. Hence, in this study, we assessed a new biomarker, 19 
lymphocyte-AUC, as a new predictive factor for immune reconstitution after allo-20 
HSCT by evaluating its impact on viral reactivation/infection. 21 
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Data collection 2 
A total of 286 patients who underwent their first allogeneic HSCT for 3 
hematological diseases at a single center of Kyoto University Hospital between 4 
2005 and 2017 were reviewed. Lymphocyte-AUC is defined as the sum of serial 5 
absolute lymphocyte counts under the lymphocyte count-time curve5. In the 6 
analysis of HHV-6 reactivation, lymphocyte-AUC values from day 0 to day 15 7 
were calculated in patients who survived over 15 days after the transplant, as 8 
most cases of HHV-6 virus reactivation occurred from day 15 to day 30. 9 
Regarding the analysis of other viruses (CMV, ADV, BKV, JCV, and VZV), 10 
lymphocyte-AUC values from day 0 to day 30 were calculated in patients who 11 
survived over 30 days after transplant, since infection by these viruses was 12 
mostly seen from 30 days after HSCT.  13 
This study was approved by the Institutional Review Board of Kyoto University 14 
Hospital and written informed consent was obtained from every patient. 15 
 16 
Viral detection and treatment 17 
CMV antigenemia and CMV virus infection 18 
CMVpp65 antigen was examined once weekly in every patient after an increase 19 
in the neutrophil count was ascertained and was examined additionally in patients 20 
with suspicious signs and symptoms of CMV diseases. Most of the patients were 21 
examined via the C10/C11 method, while some patients were assessed via the 22 
C7-HRP method. The results of the C7-HRP method are known to be highly 23 
correlated with those of the C10/11 method6. Both methods were performed as 24 
previously reported7–10. In cases where more than 2 positive cells within 2 slides 25 
(within 50000 WBC in C10/C11) were detected, pre-emptive therapy was given 26 
followed by close monitoring of CMV antigen6,8. 27 





HHV-6 preventive measures, reactivation, and infection 2 
The HHV-6 viral load was determined quantitatively after transplantation by 3 
multiplex PCR designed for multiple viral detection11 whenever a patient 4 
developed symptoms suspicious for HHV-6 reactivation. In patients who received 5 
CBT within the past seven years, PCR was examined consistently (every one or 6 
two weeks until 2 months after transplantation). 7 
For patients who received CBT within the past three years, foscarnet infusion was 8 
started at a maintenance dose (90mg/kg/day, adjusted by the patient’s kidney 9 
function) to prevent severe HHV-6 reactivation when patients were administered 10 
systemic steroid for immune reactions such as engraftment syndrome or acute 11 
graft-versus-host disease (aGVHD). Foscarnet at a curative dose (180mg/kg/day, 12 
adjusted by the patient’s kidney function) was injected when HHV-6 infection, 13 
including HHV-6 encephalitis, was diagnosed12. For patients with only HHV-6 14 
reactivation, who were diagnosed as serum HHV-6 positive without any 15 
symptoms, treatment was initiated based on the physician’s discretion, 16 
considering the detected viral dose (approximately 103 copies/ml) and the 17 
patient’s background. 18 
 19 
Adenovirus, BK virus, and JC virus viral infection 20 
When symptoms indicative of urinary tract infection such as hematuria emerged, 21 
serum and urinary levels of ADV, BKV, and JCV were examined by multiplex 22 
PCR11. For ADV, patients were also subjected to additional examinations when 23 
they developed hepatitis, fever, or other symptoms of infection of undetectable 24 
origin. For patients in whom ADV and BKV were detected in serum, systemic 25 
cidofovir injection was initiated at 1 mg/kg, three times a week. Meanwhile, for 26 
those in whom BKV and ADV were detected only in the urine, bladder instillation 27 




of cidofovir was preferred at 5 mg/kg for two days in a row 13–15.  1 
 2 
Endpoints 3 
The primary endpoint of this study was the occurrence of reactivation and 4 
infection with various viruses (CMV, VZV, HHV-6, ADV, BKV, and JCV) diagnosed 5 
within 180 days after HSCT. 6 
 7 
Statistical analysis 8 
Descriptive statistics were used to summarize variables related to the patient 9 
characteristics. Viral reactivation/infection, treatment-related mortality and 10 
disease relapse that occurred by day180 were calculated based on cumulative 11 
incidence curves16,17. Overall survival was evaluated by the Kaplan-Meier method. 12 
Competing events were defined as deaths without a diagnosis of viral 13 
reactivation/infection. Lymphocyte-AUC was estimated by collecting the area 14 
under the curve of lymphocyte counts in each patient from day 1 until either day 15 
15 (for HHV-6) or day 30 (for other viruses). These landmark days (day 15, day 16 
30) were determined based on a preceding analysis in which over 75% of onset 17 
cases were detected between day 15 and day 30 in HHV6 reactivation and after 18 
day 30 in CMV antigenemia. Fine and Gray’s proportional hazards model18 was 19 
used to evaluate the impact of lymphocyte-AUC on viral reactivation/infection in 20 
each patient. The following possible covariates were considered; recipient’s sex, 21 
age at transplant (<50 years old or ≥50 years old), disease diagnosis (myeloid 22 
malignancies, lymphoid malignancies, and others), disease status (complete 23 
remission [CR] or non-CR), donor type (bone marrow transplantation from 24 
unrelated donor, peripheral blood stem cell transplantation from related donor, 25 
cord blood transplant), conditioning regimen (reduced-intensity or myeloablative), 26 
GVHD prophylaxis (tacrolimus or cyclosporine in addition to mycophenolate 27 




mofetil or methotrexate), and the occurrence of acute GVHD by day 30 (only for 1 
CMV antigenemia). All covariate factors with a variable retention criterion of 2 
P<0.05 in the univariate analysis were selected and analyzed together with 3 
lymphocyte-AUC in the multivariate analysis. All statistical analyses were 4 
performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, 5 
Japan), which is a graphical user interface for R (The R Foundation for Statistical 6 
Computing, version 3.1.1, Vienna, Austria)19. 7 
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Patient characteristics 2 
Two-hundred-eighty-six patients were reviewed in the analysis of HHV-6 3 
reactivation and 283 were examined for other viral reactivation/infection (3 4 
patients died between day 15and day 30). Seventy-eight patients received 5 
transplantation from a related donor, 129 from unrelated bone marrow grafts, 6 
and 79 from unrelated cord blood units. Their median age at transplantation 7 
was 51 (range, 17–68) years. The median lymphocyte-AUC was 63 (range, 0–8 
5620)/μL at day 15 and 3880 (range, 0–118260)/μL at day 30. No apparent 9 
difference in lymphocyte-AUC was seen between different donor sources. 10 
We categorized the patients into 3 groups according to their lymphocyte-AUC 11 
count by day 15 and day 30. However, in the analysis of HHV-6 reactivation, the 12 
first tertile was 0/μL, since 129 patients showed no lymphocyte recovery by day 13 
15. Hence, we used the second tertile of 230/μL as a threshold to categorize 14 
patients into two groups in the analysis of lymphocyte-AUC by day 15: 15 
lymphocyte-AUC <= 230/μL (n=189) and lymphocyte-AUC > 230/μL (n=97) 16 
(Table 1). In the analysis of CMV antigenemia and infection, patients were 17 
categorized into three groups according to the first (2710/μL) and the second 18 
(5250/μL) tertile: low lymphocyte-AUC (n=93), middle lymphocyte- AUC (n=93), 19 
and high lymphocyte-AUC (n=97) (Table 2). 20 
 21 
HHV-6 reactivation/infection 22 
HHV-6 reactivation was detected in 48 of the 286 patients (cumulative 23 
incidence: 17.5% on day 180), of whom 8 patients developed virologically 24 
diagnosed HHV-6 encephalitis with typical neurological symptoms and viral 25 
detection in spinal fluid with or without positive findings in magnetic resonance 26 
imaging. Nine patients received foscarnet injection as prophylaxis from the 1st to 27 




4th weeks from transplantation after CBT, of whom 5 were diagnosed as HHV-6 1 
viremia after cessation of foscarnet.  2 
Multivariate analysis showed that a high lymphocyte-AUC was significantly 3 
associated with HHV-6 reactivation (high AUC group vs. low-plus-middle AUC 4 
group: HR, 1.83; P=0.048) (Figure 1). Other risk factors detected were aplastic 5 
anemia as a primary disease (HR, 5.34; P<0.001) and cord blood as a donor 6 
source (HR, 3.05; P=0.006) (Table 3). In the sub-analysis of patients with a 7 
history of HHV-6 viremia, there was no significant difference in lymphocyte-AUC 8 
between the HHV-6 encephalitis group and no-encephalitis group (median 9 
lymphocyte-AUC value, encephalitis group, 530/μL; no-encephalitis group 10 
249/μL; P=0.248). Foscarnet treatment had no prophylactic effect on HHV-6 11 
viremia (incidence: patients with foscarnet prophylaxis vs. without; 55.6% vs. 12 
37.1%). 13 
Since HHV-6 reactivation has been epidemiologically suggested to be 14 
associated with immune reactions before engraftment including pre-engraftment 15 
immune reaction in CBT20, we performed an additional analysis to examine the 16 
association between lymphocyte-AUC and the occurrence of immune-related 17 
reactions by day 15. High lymphocyte-AUC was associated with the occurrence 18 
of immune-related reactions (Odds ratio 2.02, P=0.015). However, in a 19 
stratification analysis, high-lymphocyte AUC was significantly associated with 20 
HHV-6 reactivation in patients both with and without an immune reaction by 21 
day15 (high AUC group vs. low-plus-middle AUC group, patients with immune 22 
reaction; HR, 2.41, P=0.047, patients without immune reaction; HR, 2.51, 23 
P=0.018). Meanwhile, in another stratification analysis, immune-related 24 
reactions showed no apparent association with HHV-6 reactivation in groups of 25 
patients with both a high lymphocyte-AUC and low-plus-middle lymphocyte-26 
AUC (patients with an immune reaction vs. patients without an immune 27 




reaction, high AUC group; HR, 1.73, P=0.160, low-plus-middle AUC group; HR, 1 
1.83, P=0.169) 2 
 3 
CMV antigenemia 4 
CMV antigenemia was detected in 146 of the 284 patients (cumulative 5 
incidence: 54.7% by day 180). Nine cases of CMV end organ infection 6 
occurred, 6 of which were diagnosed as CMV-related colitis/gastritis, and one 7 
each as retinitis, hepatitis, and pneumonia. Foscarnet was used for 9 patients 8 
as a prophylaxis for HHV-6. This was discontinued after day 30. No other 9 
agents were used for HHV-6 or CMV prophylaxis for the remaining 277 patients.  10 
In a multivariate analysis, the high AUC-lymphocyte group with AUC 5250/μL or 11 
above had a lower risk for CMV antigenemia than the low lymphocyte-AUC 12 
group (HR, 0.61; P=0.052). Meanwhile, the risk for CMV antigenemia was not 13 
significantly different between the middle lymphocyte-AUC group under 5250/μL 14 
and the low lymphocyte-AUC group (HR, 1.13; P=0.560) (Figure 2). Other risk 15 
factors detected in the multivariate analysis were age 50 years or older (vs. 16 
<50, HR, 1.55; P=0.017) and the occurrence of acute GVHD by day 30 (vs. no 17 
occurrence of acute GVHD; HR, 2.21; P<0.001) (Table 4). 18 
There was no association between preceding HHV-6 reactivation and the 19 
occurrence of CMV antigenemia (cumulative incidence of CMV reactivation 20 
after day 30: patients with history of HHV-6 reactivation by day 30 vs. those 21 
without, HR 1.07; P=0.746). 22 
 23 
Reactivation of other viruses 24 
A total of 27 cases in 20 patients were diagnosed as various viral reactivations, 25 
including ADV viremia (n=7), BKV viremia (n=13), JCV viremia (n=5), VZV 26 
viremia (n=1), and EBV viremia (n=1). Nine cases represented multiple viral 27 




coinfections (ADV/BKV n=4; BKV/JCV n=4; and ADV/BKV /JCV n=1). No 1 
apparent association was noted between these viral infections and the 2 
lymphocyte-AUC. 3 
Regarding the frequencies of sequential infections of these viruses, 6 of 45 4 
patients with a history of HHV-6 viremia by day 30 had a subsequent infection 5 
with ADV, BKV or JCV, and 3 of 238 patients without history of HHV-6 viremia 6 
had these infections. The cumulative incidence of ADV, BKV or JCV reactivation 7 
after day 30 was significantly higher in patients with a history of HHV-6 8 
reactivation by day 30 than in those without (HR, 11.1; P=0.001).  9 
 10 
Overall survival, relapse and treatment-related mortality 11 
No apparent association was observed between lymphocyte-AUC at day 15 and 12 
overall survival (high-AUC group vs. low-plus-middle-AUC group, HR, 0.81 13 
P=0.386), relapse (high-AUC group vs. low-plus-middle-AUC group, HR, 1.01; 14 
P=0.974) or treatment-related mortality (high-AUC group vs. low-plus-middle-15 
AUC group, HR, 0.77; P=0.477) were found. 16 
Also, neither overall survival (high-AUC group vs. low-AUC group, HR, 0.66; 17 
P=0.110, middle-AUC group vs. low-AUC group, HR, 0.63; P=0.095) nor 18 
relapse (high-AUC group vs. low-AUC group, HR, 0.821; P=0.581, middle-AUC 19 
group vs. low-AUC group, HR, 1.25; P=0.512) was significantly associated with 20 
lymphocyte-AUC at day 30. However, treatment-related mortality was 21 
associated with lymphocyte-AUC at day 30 (high-AUC group vs. low-AUC 22 
group, HR, 0.47; P=0.045, middle-AUC group vs. low-AUC group, HR, 0.33; 23 
P=0.013). 24 
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In this study, we evaluated lymphocyte-AUC at day 15 and day 30 as a predictive 2 
factor for reactivation of and infection by several viruses. HHV-6 and CMV are the 3 
two major viruses that cause various complications during the management of 4 
HSCT, negatively affecting patient mortality and morbidity. We found that 5 
lymphocyte-AUC can be used to identify patients at high risk for reactivation of 6 
these viruses. 7 
 8 
In the analysis of HHV-6 reactivation, high lymphocyte-AUC was strongly 9 
associated with viral reactivation. Since early intervention with antiviral agents is 10 
necessary to reduce HHV-6 reactivation and subsequent virus-related 11 
complications21–24, regular examination of the plasma level of HHV-6 viral load is 12 
strongly recommended for all patients, especially in those who show rapid growth 13 
of lymphocytes by day 15. In previous studies, HHV-6 reactivation was associated 14 
with a myeloablative conditioning regimen, cord blood transplantation, and 15 
immune reactions21,25 . Contrary to our expectation, an early immune reaction 16 
before engraftment had less of an impact on HHV-6 reactivation than lymphocyte-17 
AUC despite the temporary administration of systemic steroid to treat it. This 18 
finding that HHV-6 reactivation occurred with the rapid growth of lymphocytes 19 
regardless of an immune reaction and the preceding use of systemic steroid by 20 
day 15 might provide insights into the mechanism of HHV-6 growth after 21 
transplantation. Although it is not known whether the preceding HHV-6 growth 22 
increased the lymphocyte counts or the rapid growth of lymphocytes stimulated 23 
HHV-6 growth, HHV-6 expansion was accompanied by lymphocyte growth. This 24 
is consistent with previous reports which suggested that an inflammatory 25 
background caused by various sources of pathogenesis and the upregulation of 26 
several chemokines were associated with HHV-6 reactivation26–28. Viral latency 27 




of HHV-6 and its interaction with lymphocytes and chemokines in growth 1 
mechanisms remain to be disclosed. Our limited data (N=49) on lymphocyte 2 
subsets examined from day 15 to day 21 after transplantation failed to clarify 3 
which constituent of lymphocytes contributed to the growth of HHV-6 (data not 4 
shown). However, our data suggested that rapid and early growth of lymphocytes 5 
is a predictor of HHV-6 reactivation after HSCT.  6 
 7 
Regarding CMV antigenemia, only the high lymphocyte-AUC group with AUC of  8 
5250/μL or higher showed a low predicted risk of virus reactivation, indicating that 9 
sufficient recovery of lymphocytes is required for immunity against CMV 10 
reactivation. CMV antigen must be screened regularly if the lymphocyte-AUC is 11 
still low, regardless if a single-point blood count at day 30 shows that the patient’s 12 
immunity appears to have recovered. Our findings also showed that the 13 
occurrence of acute GVHD was associated with CMV reactivation, which is 14 
consistent with previous reports29,30 .  15 
 16 
In the analysis of viral infections other than HHV-6 and CMV, HHV-6 reactivation 17 
influenced the subsequent occurrence of ADV, BKV and/or JCV, which is 18 
compatible with the findings in a previous study31. This suggests that HHV-6 19 
infection may directly influence subsequent ADV/BKV/JCV infection or may 20 
simply reflect the severity of the immunocompromised status. Further prospective 21 
analysis is required to tackle this clinically important topic of coinfection and 22 
sequential viral infection in patients after HSCT. 23 
 24 
As for overall survival and treatment-related mortality, only a low lymphocyte-AUC 25 
under 2710/μL was suggested to be associated with an elevated risk for 26 
treatment-related mortality. The two major causes of treatment-related mortality 27 




after HSCT are the occurrence of GVHD and complications caused by various 1 
pathogens including bacteria, viruses and fungi. Considering that lymphocyte-2 
AUC at day 30 was not associated with the occurrence of acute GVHD or chronic 3 
GVHD (data not shown), the high risk of treatment-related mortality for low 4 
lymphocyte-AUC seems to reflect the immature immune reconstitution. Our study 5 
suggests that lymphocyte-AUC at day 30 may be a good predictor of general 6 
immune reconstitution, including antiviral immunity against CMV antigenemia. 7 
 8 
However, our study had several limitations. First, data on lymphocyte subsets 9 
were limited. Since various lineages of lymphocyte reconstitution have been 10 
suggested to be associated with HHV-6 reactivation32,33, they should be 11 
evaluated more precisely to further clarify the interaction between HHV-6 and 12 
lymphocytes. Second, since the number of cases with HHV-6 infection such as 13 
encephalitis in our hospital was limited, the impact of lymphocyte-AUC on HHV-14 
6 infection was not examined. Studies with a larger cohort are required to 15 
examine the impact of lymphocyte-AUC on symptomatic HHV-6 reactivation. 16 
 17 
In conclusion, increases in lymphocyte-AUC at day 15 and day 30 may help to 18 
identify patients who are at high risk for HHV-6 reactivation, low risk for CMV 19 
reactivation and treatment-related mortality, respectively. A prospective clinical 20 
study of pre-emptive therapy with antiviral agents against HHV-6 for patients with 21 
high lymphocyte-AUC at day 15 is expected in the future.  22 
 23 
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Figure legends 1 
Figure 1 Cumulative incidence of HHV-6 reactivation 2 
Figure 2 Cumulative incidence of CMV antigenemia 3 
Table1 Patient characteristics (Day15) 
Total
n*1 n %*2 n % P-Value
51 (17-68) 0.581
Male 168 108 57.1 60 61.9
Female 118 81 42.9 37 38.1
Sibling 78 51 27.0 27 27.8
Unrelated BM 129 99 52.4 30 30.9
Unrelated CB 79 39 20.6 40 41.2
AML/MDS 172 115 60.8 57 58.8
ALL/other leukemias 61 41 21.7 20 20.6
Malignant lymphoma 45 25 13.2 20 20.6
Aplastic anemia 8 8 4.2 0 0.0
CR 130 79 41.8 51 52.6
non CR 156 110 58.2 46 47.4
Myeloablative 149 101 53.4 48 49.5
Reduced intensity 137 88 46.6 49 50.5
CI 23 7 3.7 16 16.5
CI+MMF 56 28 14.8 28 28.9
CI+MTX 161 119 63.0 42 43.3
CI+MMF+MTX 44 34 18.0 10 10.3
regimens containing䚷ATG 2 1 0.5 1 1.0
*1n indicates the number of patients with each characteristics
*2% indicates the percentage of patients in each group
*3Age indicates patients' age at transplantation
Calcinerin inhibitors include Tacrolimus and Cyclosporin




Abbreviation: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CR, complete remission; 
BM, bone marow; CB, cord blood; GVHD, graft-versus-host disease; CI, Calcinerin inhibitor; MMF, mycophenolate mofetil; MTX, 














Low, Middle AUC(<230/μ䡈) (n=189)
Disease status
52 (18-68)
 Group by Lymphocyte-AUC by day15 (n=286)
Table1
Table2 Patient characteristics (Day30)
Total
n*1 n %*2 n % n % P-Value
51 (17-68) 0.581
Male 117 29 31.2 44 47.3 44 45.4
Female 166 64 68.8 49 52.7 53 54.6
Sibling 77 19 20.4 22 23.7 36 37.1
Unrelated BM 128 30 32.3 44 47.3 54 55.7
Unrelated CB 78 44 47.3 27 29.0 7 7.2
AML/MDS 169 59 63.4 56 60.2 54 55.7
ALL/other leukemias 61 15 16.1 22 23.7 24 24.7
Malignant lymphoma 45 13 14.0 14 15.1 18 18.6
Aplastic anemia 8 6 6.5 1 1.1 1 1.0
CR 130 33 35.5 52 55.9 45 46.4
non CR 153 60 64.5 41 44.1 52 53.6
Myeloablative 146 47 50.5 48 51.6 51 52.6
Reduced intensity 137 46 49.5 45 48.4 46 47.4
CI 22 10 10.8 10 10.8 2 2.1
CI+MMF 55 27 29.0 20 21.5 8 8.2
CI+MTX 161 45 48.4 44 47.3 72 74.2
CI+MMF+MTX 43 11 11.8 19 20.4 13 13.4
regimens containing䚷ATG 2 0 0.0 0 0.0 2 2.1
I 18 4 4.3 6 6.5 8 8.2
II 51 13 14.0 22 23.7 16 16.5
III 10 3 3.2 2 2.2 5 5.2
IV 2 0 0.0 2 2.2 0 0.0
*1n indicates the number of patients with each characteristics
*2% indicates the percentage of patients in each group
*3Age indicates patients' age at transplantation
Calcinerin inhibitors include Tacrolimus and Cyclosporin
GVHD prophylaxis <0.05
GVHD (by 
day30) grade at 
onset
0.577
Abbreviation: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CR, complete remission; BM, bone marow; CB, cord blood; GVHD, graft-
versus-host disease; CI, Calcinerin inhibitor; MMF, mycophenolate mofetil; MTX, methotrexate; ATG, antithymocyte globulin















Table 3 Univariate and multivariate analysis of HHV-6 reactivation
HR 95% CI P-Value HR 95% CI P-Value
㻨50 1.00 reference
䍻50 0.63  (0.32-1.28) 0.201
Male 1.00 reference
Female 1.29  (0.95-1.75) 0.102
Sibling 1.00 reference 1.00 reference
Unrelated BM 0.54  (0.21-1.40) 0.204
Unrelated CB 4.53  (2.17-9.45) <0.001 3.05 (1.38-6.72) 0.006
AML/MDS 1.00 reference 1.00 reference
ALL/other leukemias 0.78  (0.36-1.70) 0.527
Malignant lymphoma 1.12  (0.52-2.42) 0.779
Aplastic anemia 3.24  (1.29-8.16) 0.012 5.34 (2.38-12.00) <0.001
CR 1.00 reference
non CR 0.65  (0.39-1.08) 0.096
Myeloablative 1.00 reference
Reduced intensity 0.91  (0.52-1.60) 0.749
CI 1.00 reference 1.00 reference
CI+MMF 2.37  (0.91-6.16) 0.077
CI+MTX 0.26  (0.09-0.75) 0.013 0.35 (0.15-0.84) 0.019
CI+MMF+MTX 0.67  (0.21-2.12) 0.493
regimens containing䚷ATG 2.07 (0.35-12.33) 0.421
Low,Middle-AUC*2 1.00 reference 1.00 reference
High-AUC*3 2.44 (1.40-4.23) 0.002 1.83 (1.01-3.34) 0.048
*1Age indicates patients' age at transplantation
*2Low,Middle-AUC indicates group of patients with lymphocyte-AUC under 230/μl
*3High-AUC indicates group of patients with lymphocyte-AUC of  230/μl or over
Calcinerin inhibitors include Tacrolimus and Cyclosporin
Abbreviation: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CR, complete 
remission; BM, bone marow; CB, cord blood; GVHD, graft-versus-host disease; CI, Calcinerin inhibitor; MMF, mycophenolate mofetil; 
MTX, methotrexate; ATG, antithymocyte globulin













Table 4 Univariate and multivariate analysis of CMV antigenemia
HR 95% CI P-Value HR 95% CI P-Value
㻨50 1.00 reference 1.00 reference
䍻50 1.46  (1.01-2.09) 0.042 1.55 (1.08-2.21) 0.017
Male 1.00 reference
Female 0.90  (0.77-1.08) 0.273
Sibling 1.00 reference
Unrelated BM 1.08  (0.71-1.63) 0.731
Unrelated CB 1.47  (0.22-1.78) 0.075
AML/MDS 1.00 reference
ALL/other leukemias 1.30  (0.84-2.00) 0.237
Malignant lymphoma 0.93  (0.54-1.60) 0.800
Aplastic anemia 1.13  (0.41-3.07) 0.817
CR 1.00 reference
non CR 1.01  (0.75-1.35) 0.960
Myeloablative 1.00 reference
Reduced intensity 0.98  (0.70-1.36) 0.882
CI 1.00 reference
CI+MMF 0.83  (0.44-1.54) 0.549
CI+MTX 0.66  (0.37-1.17) 0.154
CI+MMF+MTX 1.06 (0.56-2.00) 0.847
regimens containing䚷ATG 1.14 (0.67-1.93) 0.618
aGVHD by no 1.00 reference 1.00 reference
occurrence 1.94 (1.37-2.75) <0.001 2.21 (1.49-3.29) <0.001
Low-AUC*2 1.00 reference 1.00 reference
Middle-AUC*3 1.27  (0.87-1.84) 0.212 1.13  (0.74-1.73) 0.560
High-AUC*4 0.63  (0.40-0.98) 0.041 0.61  (0.37-1.01) 0.052
*1Age indicates patients' age at transplantation
*2Low-AUC indicates group of patients with lymphocyte-AUC under 2710/μl
*3Middle-AUC indicates group of patients with lymphocyte-AUC of  2710/μl or over and under 5250/μl
*4HIgh-AUC indicates group of patients with lymphocyte-AUC of 5250/μl or over
Calcinerin inhibitors include Tacrolimus and Cyclosporin
Abbreviation: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CR, complete 
remission; BM, bone marow; CB, cord blood; GVHD, graft-versus-host disease; CI, Calcinerin inhibitor; MMF, mycophenolate mofetil; 
MTX, methotrexate; ATG, antithymocyte globulin
Age*1
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